Keyphrases
Randomized Placebo-controlled Trial
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Overweight Patient
100%
Remission
100%
Obese Patients
100%
Lorcaserin
100%
Pre-diabetes (pre-DM)
50%
Placebo
33%
Incident Diabetes
33%
Normoglycaemia
33%
Diabetes
25%
Patients with Diabetes
25%
Lifestyle Modification
16%
High Risk
16%
Weight Loss
16%
Atherosclerotic Vascular Disease
16%
Without Diabetes
16%
Hazard Ratio
8%
Risk Factors
8%
Intention-to-treat
8%
Safety Outcomes
8%
Cox Proportional Hazards Model
8%
Twice Daily
8%
Time-to-event Analysis
8%
Efficacy Endpoint
8%
Hemoglobin A1c (HbA1c)
8%
Serious Complications
8%
Body Mass Index
8%
Hyperglycemia
8%
Receptor Agonist
8%
Vascular Complications
8%
Metabolic
8%
Diabetes Risk
8%
Overweight or Obesity
8%
Hypoglycemia
8%
Diabetes Remission
8%
Glycated Hemoglobin A1c
8%
Metabolic Health
8%
Diabetes Prevention
8%
Severe Hypoglycemia
8%
Serotonin 2C Receptor
8%
Chronic Management
8%
Selective Serotonin
8%
Weight Management Program
8%
Eisai
8%
Net Weight
8%
Medicine and Dentistry
Obesity
100%
Maturity Onset Diabetes of the Young
100%
Placebo
100%
Lorcaserin
100%
Diabetes
83%
Impaired Glucose Tolerance
50%
Patient with Diabetes
25%
Lifestyle Modification
16%
Vascular Disease
16%
Hemoglobin A1c
16%
Hypoglycemia
16%
Hazard Ratio
8%
Intention-to-Treat Analysis
8%
Body Mass Index
8%
Proportional Hazards Model
8%
Hyperglycemia
8%
Diabetes Prevention
8%
Glycated Hemoglobin
8%
Weight Management
8%
Microvascular Complication
8%
Serotonin 2C Agonist
8%
Pharmacology, Toxicology and Pharmaceutical Science
Obesity
100%
Remission
100%
Placebo
100%
Lorcaserin
100%
Non Insulin Dependent Diabetes Mellitus
100%
Impaired Glucose Tolerance
50%
Vascular Disease
16%
Hemoglobin A1c
16%
Hypoglycemia
16%
Glycosylated Hemoglobin
8%
Hyperglycemia
8%
Serotonin 2C Agonist
8%
Biochemistry, Genetics and Molecular Biology
Lorcaserin
100%
Impaired Glucose Tolerance
50%
Glucose Blood Level
33%
Body Mass
8%
Hyperglycemia
8%
Receptor Agonists
8%
Glycated Hemoglobin
8%
5-HT2C Receptor
8%